Bone Health in Teens With Obesity Taking GLP-1 Medicines
Compares bone health in teens with obesity on GLP-1 medicine or lifestyle care.
Key facts
- Who runs it
- University of Virginia
- Where
- Charlottesville, United StatesSee the site
- Trial code
- Registry title
- Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 31 Jul 2025
- Expected to end
- 30 Apr 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- GLP-1 receptor agonist
- Lifestyle intervention
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers and young adults aged 12 to 21 with obesity. They either start a GLP-1 receptor agonist medicine or follow usual lifestyle care. Researchers compare bone health over 24 months.
- Age
- 12 to 21 years
- Sex
- All sexes can join.
- Disease stage
- Obesity, with BMI at or above the 95th percentile for age and sex. People in the GLP-1 group must have already tried to lose weight with usual care.
- Earlier treatment
- Starting GLP-1 receptor agonist therapy (not dulaglutide or exenatide), or following usual care. Orlistat taken before GLP-1 therapy because of insurance rules is allowed.
Main reasons for not taking part
- Current or past pregnancy or breastfeeding
- More than 5 kg (11 lb) weight loss over 3 months
- Medicines that affect weight or bone, such as metformin, phentermine, topiramate, or glucocorticoids
- Depot medroxyprogesterone acetate (DMPA) contraception
- Untreated thyroid problems, HbA1C above 8% (64 mmol/mol), or past weight-loss (bariatric) surgery
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- • Adolescents and young adults with obesity 12-21 years old starting GLP-1 RA therapy (except for dulaglutide or exenatide) or followed with 'usual' care
- Diagnosis of obesity (BMI ≥ 95th percentile for age and sex). The FDA has approved the use of GLP-1 RAs (liraglutide and semaglutide) for adolescents ≥ 12 years old with BMI ≥ 95th percentile for age and sex, and tirzepatide for adults with obesity. Those in the GLP-1 RA arm must have demonstrated efforts at weight loss with 'usual' care, and consistent compliance with appointments and recommendations
- Participants must demonstrate sufficient maturity, psychological stability and cognitive capacity to recognize the significance of being on medical therapy and implement required behavioral changes
- Patients taking orlistat as a precursor to GLP-1 RA therapy due to insurance requirements may be included given minimal effects on weight
- Use of the following contraceptive methods is permitted: Combine oral contraceptives (COCs); continuous oral progestin; Progestin-releasing intrauterine device (IUD); Progestin implant; transdermal patch
- Patients with celiac disease will be included if the condition is well controlled and they are on a gluten free diet with normal 25(OH)D levels confirmed by clinical labs within 3 months of enrollment in the study. If a patient does not have recent 25(OH)D results, we will add this to the screening labs
Who cannot take part
- • Current or previous history of pregnancy and breast feeding
- Use of dulaglutide and exenatide (of the GLP-1 RAs) given minimal weight loss with these drugs
- Use of medications such as metformin, phentermine, or topiramate that may cause weight loss, or obesogenic antipsychotic medications if treated for <3 months, or if dosage is not stable for >2 months
- Untreated thyroid dysfunction or on stable dose for <3 months. Primary thyroid dysfunction will be defined as: a TSH ≥ 10 IU/L or low per given reference range with unknown thyroid antibody status, or an abnormal TSH if known positive antibodies. Patients with known hypothyroidism will be included if appropriately treated with levothyroxine and have a normal TSH. For patients with secondary hypothyroidism (deficient production of TSH from the pituitary gland causing hypothyroidism), normal free T4 concentrations (and not TSH alterations) will be used for study inclusion, and recent adjustments in the levothyroxine dose will be permissible as long as free T4 concentrations are in the normal range at dose adjustment (as dose adjustments are often made to get free T4 concentrations in the upper half of the normal range when assessed levels are in the lower half of the normal range). Patients with hyperthyroidism will be excluded given known deleterious effects on both weight and bone metabolism
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 if in the GLP-1 RA group
- Medical conditions known to impact weight or bone density, such as chronic gastrointestinal disorders (including inflammatory bowel disease), other inflammatory conditions, such as rheumatoid arthritis or ankylosing spondylitis, untreated thyroid disease, and hypercortisolemia
- History of metabolic and bariatric surgery
- Medications other than calcium or vitamin D that affect bone, such as systemic glucocorticoids, phenytoin, phenobarbitone (unless there is a washout period of 3 months prior to enrollment if discontinuation is medically permissible)
- HbA1C >8% (to avoid deleterious effects on bone from uncontrolled T2DM)
- > 5 kg weight loss over 3 months given the known impact of significant weight loss on bone density
- Female participants on hormonal contraception will be excluded if this involves use of depot medroxyprogesterone acetate (DMPA). DMPA has profound deleterious effect on bone density, which could confound study outcomes related to bone health. Rationale: DMPA has a well-documented deleterious effect on bone density, which could confound study outcomes related to bone health or metabolic parameters
- Smoking >10 cigarettes/day given deleterious effects on bone; substance abuse per DSM-5
- Weight >450 lbs due to limits for DXA scanners
- Judged by the investigators to be inappropriate for the study for other reasons not detailed above
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 21 years old?
Where in United States
- University of Virginia Medical CenterCharlottesville, United StatesContact: Melissa G Gilrain, BSTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those with similar weight followed by lifestyle management.
Read full original descriptionShow less
Participants will:
* Take GLP-1RA as prescribed or continue to work on lifestyle management for weight loss * Take provided calcium and vitamin D supplements * Attend 6 study visits over 24 months with two at the beginning and then every 6 months that include:
* History and Physical Exams * Lab Work * Imaging studies * Questionnaires * 24-hour dietary recalls
The 2 groups in the trial
- GLP-1 Receptor AgonistExisting treatment, for comparison
- Lifestyle InterventionPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Bone Metabolism in Adolescents Undergoing GLP-1 Receptor Agonist Therapy
- Plain-language title
- Bone Health in Teens With Obesity Taking GLP-1 MedicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06903923, who can take part
- Record updated
- 17 April 2026